Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 5Gliosarcoma 4Squamous Cell Carcinoma of Head and Neck 3Glioma 3Brain Neoplasms 3Treatment-Refractory Solid Tumors 2Salivary Gland Neoplasms 2Central Nervous System Neoplasms 2Tongue Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1HPV-Negative Squamous Cell Carcinoma 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Bites and Stings 1Astrocytoma 1Advanced Solid Tumors 1

Interventions

Temozolomide 11Filgrastim 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Carmustine 4Thiotepa 3Radiation 3Etoposide 3Carboplatin 3Azacitidine 3Automobiles 3sargramostim 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2ONC206 2O(6)-benzylguanine 2Nivolumab 2Melphalan 2Immunohistochemistry 2Imiquimod 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 21-methyltryptophan 2vitespin 1veliparib 1vatalanib 1trametinib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ependymoma × Hydroxyurea × Clear all
NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡